Vincent Serra Email & Phone Number

Île-de-France, France

Île-de-France, France

Lyon, Auvergne-Rhone-Alpes, FR

Suresnes, Île-de-France, FR

Suresnes, Île-de-France, FR

Suresnes, Île-de-France, FR

Consulting activities for Venture Funds, Pharmaceutical and Biotech companies for Therapeutic drugs (NCE/NBE) in Oncology, CNS, Immunology and Class III medical Devices- Due diligence,- Strategic and business development plan- Part time managment

Cerebrum therapeutics was a biotech related project based on the development of proprietaries new drug candidates in neurodegenerative diseases and brain injuries.

Toulouse, Occitanie, FR

Toulouse, Occitanie, FR

• Executive manager of Pierre Fabre Fund for Innovation. Manager of potential sourcing projects that may involve significant risk-taking. Main contact and decision-maker between the executive partners and the top.
• Worldwide active identification of highly potential innovations at an early stage in immuno-oncology (new checkpoint inhibitors, bispecific, ADC, new Ab generation platforms, …), NEC in oncology and Dermatology
• Co-piloting partners’ strategy with optimization of the innovation process
• Development of scientific synergies between the partners’ teams and our experts
• Innovation management and valorization, ROI for the partner and the group

Paris, Île-de-France, FR

• Stock-market listing of ABIVAX, a biotech specialized in vaccines, therapeutic anti-viral (AIDS, hepatitis B…) and antibodies. An initial public offering (IPO) successfully carried out in 2015, and through which ABIVAX.
• Creation of ABIVAX through the merger of Wittycell with 2 others biotech companies belonging to the Truffle Capital investment fund.
• Management of ABIVAX Biologic patent portfolio (vaccines, antiviral, antigen delivery system, antibodies): 25 patent families, 196 patents (56% granted)
• Responsibility for the R&D vaccines/antibodies projects, from the early stage projects to Phase II. Development of scientific synergies between the internal and external R&D teams of academic/private experts worldwide.

• Appointed CEO by Capital investment fund with the mission to analyze scientific projects from biotechnology companies and innovating structures, and to launch NewCo. Focus on Immunology, Antibodies and cell line.
• Screening and reviewing programs. Identifying opportunities and assessing the adequate technology
• Providing strategic and technological watch, sourcing opportunities and presenting Wittycell to potential stakeholders during international events and meetings
• Negotiating with scientific and policy makers from Cuba, in a country subject to an embargo. Identifying, analyzing and negotiating license agreements with the Scripps Research Institute (California), the University of.
• Creating, setting and coordinating research and development programs in immunology (NKT agonists selection from Hit to lead, GMP manufacturing, and clinical trial for Th1 adjuvant use in therapeutic vaccine for.
• Assessing and valuing potential innovations in immuno-oncology (oncolytic virus, etc)

US

• CEO and CSO of Anosys, a biotechnology company specialized in the development of products particularly innovative, based on the use of exosomes secreted by mDC derived cells process from leucopack. A company.
• Creation and structural development of the company
• Implementation and follow up of several research programs between Anosys and several American and European academic laboratories in Immuno-oncology
• Implementation of the cell line process, the QC and QA specifications, in close contact with the regulatory agencies. Determination and realization of the preclinical, tox and manufacturing packages in 18 months
• Coordination of R&D teams, QA, QC, manufacturing and clinical with direct interaction with the US headquarters (with a staff of 35 in France and 65 in the US). Implementation of the R&D and manufacturing Class B site.
• 11 patent families in 20 countries, 164 patents (60% granted)

Management and coordination on works about research and development within a biotechnology company, following the completion of a doctoral thesis in immunology titled: “The role of complement in antigen presentation.”- Evaluation of monocytes purification systems from leucopack- Optimization of a cell differentiation process of monocytes into dendritic.

Paris, France, FR

Findings on the role of the non-specific immune response in the immunogenicity of soluble antigenDetermination of the endosomal and lysosomal proteases degradation process of several antigenic proteins.